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Background. Biofilms are sophisticated communities of matrix-encased and surface-attached bacteria that exhibit a distinct and specific resistant/tolerant phenotype
to almost all antibacterial agents, with activity reduced 10- to 1,000-fold. Interestingly,
this augmented resistance rapidly reverts when bacteria detach from the biofilm and
return to a planktonic state. However, in this in vitro pharmacokinetic and pharmacodynamic (PK/PD) model we are able to expose biofilms to shear rates that are consistent with human interface and mimic antibiotic penetration and diffusion pathways
from serum antibiotic concentration in humans.
Methods. Methicillin-susceptible ATCC 29213 and MRSA 494 strains were evaluated. Initial susceptibility tests were performed by broth microdilution method. Time
kill studies were performed to identify synergy patterns for liposomal and commercial
antibiotics. Biofilm eradication was investigated using antibiotics vancomycin (VAN)
(commercial) vs. liposomal VAN (VAN-L) (Patent#17-1460) and also combination
of VAN- cefazolin (commercial) vs. liposomal vancomycin and liposomal cefazolin
(CFZ-L) (Patent# 17-1460) in biofilms for strain MRSA 494. Biofilms were generated
overnight using the BioFlux Microfluidic system (Fluxion BioSciences) at constant and
continuous shear rates to optimize biofilm attachment and creation. Perfusion of antibiotic solutions (free peak concentration) was applied over a 24 h time period. Time
lapse pictures were recorded to determine antibiotic biofilm eradication rates over 18h
of incubation and pictures were analyzed using Bioflux Montage software.
Results. MIC values demonstrated a 2-fold reduction for liposomal vancomycin
vs. commercial vancomycin. Also, combination of liposomal VAN MIC in presence
of CFZ-L showed a 15.87-fold reduction in comparison to commercial VAN for 494.
Overall, our biofilm results demonstrated a 43.6% improved eradication using VAN-L
and CFZ-L combination in comparison to commercial VAN-CFZ combination. We
also observed 5.7% improved eradication using VAN-L vs. commercial VAN.
Conclusion. Liposomal form of VAN and CFZ combinations are a promising
approach to improved efficacy and reduced VAN resistance in S. aureus biofilms.
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Background. Urinary tract infection (UTI) is one of the most common infectious diagnoses and in 2007 accounted for 10.5 million primary care visits in the US
Advancing age and comorbidities, such as chronic kidney disease (CKD) and diabetes,
affect antimicrobial prescribing habits. Sulfamethoxazole/trimethoprim (SMX-TMP),
nitrofurantoin, and fosfomycin are first-line recommendations for uncomplicated
cystitis. In an aging male population with potential allergies or contraindications to
the above, fosfomycin is a potential option for treatment.
Methods. A retrospective chart review of fosfomycin prescribing habits at a large
VA academic medical center. Patients were selected based on fosfomycin prescription
in both inpatient and outpatient settings from January 1, 2004 to December 5, 2017.
Data reviewed included indication, organism(s), susceptibility, duration of treatment,
CKD, and clinical success. Treatment success was defined as no representation with
UTI symptoms for 30 days.
Results. 117 cases of UTI in which fosfomycin was used were identified with a
median patient age of 70 years old and 90% male. Twenty-five were uncomplicated
cystitis, 49 complicated cystitis, and 34 catheter associated infections. Treatment
success was obtained in 92% of the uncomplicated cystitis cases, 76% in complicated
cystitis cases, and 67% in catheter associated UTIs. In half of all the cases an ESBL bacterium was isolated and 79% were successfully treated with fosfomycin. The most common pathogen identified was E. coli 58/118 (49%), followed by Klebsiella 25/118 (21%).
Conclusion. Fosfomycin is an antibiotic recommended for simple cystitis due to
its safety profile, less collateral damage (gut flora disturbance), and low resistance as
currently known. This review displays the largest ESBL cohort identified in the literature and uniquely used in a predominant male population. These findings suggest
that ESBL producing bacteria can be treated successfully with fosfomycin in a male
population as well as uncomplicated cystitis. However, caution should be used with
catheterized patients as treatment was less effective regardless of isolated bacteria.
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Background. Scedosporiosis is a rare fungal infection with high mortality rates.
Because clinical trials are hard to conduct, we developed a murine model for evaluating
the efficacy of currently used antifungals in treating scedosporiosis.
Methods. MIC of isavuconazole (ISAV), posaconazole (POSA), voriconazole (VORI), and micafungin (MICA) were determined against 9 clinical isolates of
Scedosporium apiospermum, S. boydii and Lomentospora prolificans using the CLSI
M38 method. ICR mice were immunosuppressed with cyclophosphamide (200 mg/kg)
and cortisone acetate (500 mg/kg) on days −2, +3, and +8 relative to intratracheal
infection with 3.0 × 107 cells of S. apiospermum. For survival studies, treatment with
placebo (vehicle control), ISAV (110 mg/kg, tid, po), POSA (30 mg/kg, tid, po), VORI
(40 mg/kg, qd, po), MICA (3 or 10 mg/kg, qd, ip) or a combination of MICA (10 mg/
kg) + ISAV (110 mg/kg) began 16 h post infection and continued for 7 days. For fungal
burden studies, dosing began 8 h post infection and continued for 3 days. Mice were
sacrificed on day +4. Survival and tissue fungal burden (by qPCR) served as efficacy
endpoints.
Results. S. apiospermum was the most susceptible to all 4 antifungals with MICA
MIC of 0.25 μg/mL and azole MICs of 1 μg/mL. S. boydii was also susceptible to
MICA (0.125–0.5 μg/mL) but with variable susceptibility to azoles (1–16 μg/mL). In
contrast, L. prolificans strains were resistant (MICA MIC 2–4 μg/mL and azole MIC
>16 μg/mL). S. apiospermum DI16-478 was used to test in vivo efficacy. Only MICA
(10 mg/kg) treatment prolonged survival of mice (n = 10) vs. placebo (median survival
time = 8 days for MICA vs. 5 for placebo, P < 0.03 by log rank) and reduced fungal
burden in lungs (primary target organ), brains and kidneys (P ≤ 0.02, by Wilcoxon
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Background. Avibactam (AVI) is a broad-spectrum intravenous non-β-lactam/
β-lactamase inhibitor with no reported activity against metallo-β-lactamases such as
New Delhi metallo-β-lactamases (NDM). Structural similarities between β-lactamases
and bacterial penicillin-binding proteins (PBPs) have led investigators to explore and
confirm the hypothesis that AVI may interact with PBPs of several Gram-negative and
-positive bacterial species. Potent synergy has also been observed between AVI and
peptide antibiotics such as polymyxin B. We hypothesized that sub-bacteriostatic concentrations of AVI may bind PBPs to weaken cell wall integrity and enhance lysis by
the membrane attack complex of complement and by endogenous cationic antimicrobial peptides (AMPs) such as human cathelicidin LL-37. Sensitization to endogenous
AMPs could improve killing by neutrophils and platelets that release these effectors
upon degranulation.
Methods. Using NDM K. pneumoniae (NDM-KP) as a model, we performed
LL-37 kill curves and killing assays with human serum, neutrophils and platelets in the
presence or absence of AVI 4 μg/mL against NDM-KP.
Results. AVI alone lacked in vitro activity against NDM-KP. Addition of AVI to a
physiological achievable concentration of LL-37 (2 mM) was bactericidal and resulted
in an 8-log10 reduction (below detection limit) in recoverable NDM-KP CFU at 6 and
24 h; no bactericidal activity was seen in bacteria treated with LL-37 or AVI alone (P <
0.0001). AVI pretreatment dramatically sensitized NDM-KP to neutrophil and platelet
killing (P < 0.0001 and P < 0.01, respectively). AVI also sensitized NDM-KP to 20%
human serum, resulting in 8-log10 reduction in recoverable NDM-KP CFU within 6 h
(P < 0.0001), an effect abrogated by heat treatment to inactivate complement.
Conclusion. AVI demonstrates potent synergy with peptide antibiotics and the
innate immune system in vitro. Since AVI alone has scant direct antimicrobial activity
and no direct inhibitory effect on metallo-β-lactamases, it is less likely to increase
selective pressures toward antibiotic resistance. The use of AVI in combination with
other antibiotics against drug-resistant bacterial pathogens warrants further study.
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